Matthew Osborne
About Matthew Osborne
Current Role: Head of ATP Portfolio Company Investor Relations
Matthew Osborne currently holds the position of Head of ATP Portfolio Company Investor Relations. In this role, he oversees the investor relations strategies for ATP's portfolio companies, ensuring clear communication between the companies and their investors. He utilizes his extensive experience in financial communications and investor relations to support and guide ATP's investment strategies.
Educational Background: Syracuse University and Northeastern University
Matthew Osborne earned a Bachelor of Science degree in Biology from Syracuse University. He also holds an MBA from the D'Amore-McKim School of Business at Northeastern University. His strong educational foundation in both the sciences and business has enabled him to excel in various high-level roles within the biotechnology and pharmaceutical industries.
Previous Experience: Senda Biosciences, OncXerna Therapeutics, and Unum Therapeutics
Prior to his current role, Matthew Osborne served as Chief Financial Officer at several companies, including Senda Biosciences, OncXerna Therapeutics, and Unum Therapeutics, now known as Cogent. In these positions, he managed financial operations, helped secure funding, and played a crucial role in guiding the companies through strategic growth phases.
Experience in Investor Relations at Voyager Therapeutics and Synageva BioPharma
Matthew Osborne also held the position of Vice President of Corporate Affairs, Communications, and Investor Relations at Voyager Therapeutics. Additionally, he served as Vice President of Investor Relations and Communications at Synageva BioPharma, which was later acquired by Alexion. His responsibilities included overseeing investor communications and managing corporate affairs, which contributed to the companies' growth and development.
Early Career: Lazard Capital Markets and Leerink Swann
Matthew Osborne began his career as a biotechnology sell-side equity analyst at Lazard Capital Markets. In this role, he launched several biotech IPOs and analyzed blockbuster drug developments. Earlier in his career, he worked as an associate analyst at Leerink Swann, now known as Leerink Partners. These positions provided him with valuable insights into the biotechnology market and investor dynamics.